Holen Sie sich die Stockscreener-App
24.36
4.33%
1.01
Handel nachbörslich:
24.36
Schlusskurs vom Vortag:
$23.35
Offen:
$23.26
24-Stunden-Volumen:
466.72K
Relative Volume:
0.68
Marktkapitalisierung:
$958.32M
Einnahmen:
$734.86M
Nettoeinkommen (Verlust:
$5.14M
KGV:
194.88
EPS:
0.125
Netto-Cashflow:
$132.71M
1W Leistung:
+9.19%
1M Leistung:
-0.61%
6M Leistung:
+2.31%
1J Leistung:
-5.40%
1-Tages-Spanne:
$22.87
$24.70
1-Wochen-Bereich:
$21.92
$24.70
52-Wochen-Spanne:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.36 | 918.77M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira (PCRX) Addresses Stockholder Concerns Over Misleading Cla - GuruFocus
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy - The Manila Times
Pacira BioSciences Sets the Record Straight Regarding - GlobeNewswire
Pacira shareholders lobbied by hedge fund board nominees - MSN
Trading the Move, Not the Narrative: (PCRX) Edition - Stock Traders Daily
PCRX Stock Chart | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
DOMA Perpetual Capital Issues a Press Release to Pacira BioSciences Shareholders - marketscreener.com
Doma Perpetual urges Pacira BioSciences shareholders to judge sale price adequacy - marketscreener.com
Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy - TradingView
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC - PR Newswire
DOMA Perpetual Issues a Press Release to Shareholders of Pacira BioSciences - marketscreener.com
PCRX: DOMA Capital Advocates for Change in Pacira BioSciences Bo - GuruFocus
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences - Nasdaq
Pacira Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pacira BioSciences Issues Investor Presentation for Shareholders - marketscreener.com
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders - The Manila Times
Pacira BioSciences Files Investor Presentation Highlighting - GlobeNewswire
Pacira Q1 earnings miss estimates on higher costs, revenues rise y/y - MSN
Do options traders know something about Pacira BioSciences stock we don't? - MSN
Pacira BioSciences: Exparel Still Supports My Original Bull Case (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences, Inc.Common Stock (NQ: PCRX - The Chronicle-Journal
(PCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pacira BioSciences stock (US6951271005): Activist investor DOMA nominates three board directors - AD HOC NEWS
UBS Group AG Has $14.46 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciencesAlong with its Definitive Proxy Statement & WHITE Proxy CardUrging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates - Sahm
DOMA Perpetual nominates three directors to Pacira board By Investing.com - Investing.com India
Concerns Rise Over Pacira BioSciences' (PCRX) Board Management S - GuruFocus
Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DOMA Perpetual nominates three directors to Pacira board - Investing.com UK
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences - Yahoo Finance
Vanguard Group Inc. Sells 384,612 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Capital Solicits Proxies from Shareholders of Pacira BioSciences - marketscreener.com
Pacira BioSciences sends letter to stockholders reiterating superior qualifications of its board nominees - marketscreener.com
Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees - TradingView
Activist DOMA (PCRX) Seeks CEO Removal, Board Seats; Pushes Sale Vote - Stock Titan
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees - GlobeNewswire
HC Wainwright Expects Lower Earnings for Pacira BioSciences - MarketBeat
Pacira Q1 2026 slides: EXPAREL growth accelerates, margins compress By Investing.com - Investing.com Australia
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts - Investing.com UK
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts By Investing.com - Investing.com Australia
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
10 new Pacira hires get stock options and restricted units - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira BioSciences Reports Strong Q1 2026 Results and Highlights Success of 5x30 Strategy, Urges Stockholders to Vote "FOR" Board Nominees - Quiver Quantitative
Pacira BioSciences Mails Letter to Stockholders - The Manila Times
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill
Contact - FinancialContent
MSN Money - MSN
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pacira Biosciences Inc-Aktie (PCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cross Shawn | Chief Financial Officer |
Apr 23 '26 |
Sale |
25.16 |
12,941 |
325,596 |
105,341 |
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):